$3.19
+6.16%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.14
From 52W high−66.06%
Volume1323.00
Market cap$5.59M
P/E (TTM)—
P/S (TTM)96.2x
Div yield—
Key dataNov 4, 2026
Open
$3.14
From 52W high
−66.06%
Volume
1323.00
Market cap
$5.59M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
P/E (TTM)
—
RSI (14)
44.9
MomentumView details →
1D Return
+6.16%
YTD Return
−61.92%
SummaryUpdated Jun 1, 2026
Addex Therapeutics Ltd (NASDAQ:ADXN) is a Swiss development-stage biopharmaceutical company founded in 2002 and headquartered in Geneva. The company specializes in discovering and developing small-molecule pharmaceutical products targeting central nervous system disorders through its proprietary allosteric modulation technology platform. After going public in February 2020, Addex has evolved from a traditional biotech focused on advancing its own pipeline to a more asset-light model, having spun out its preclinical programs into Neurosterix in 2024 while retaining key partnerships and a focused development strategy.
Similar companies
Latest newsMore news →
Addex Therapeutics Ltd. issued 93,000,000 new registered shares with a nominal value of CHF 0.01 each, fully subscribed by its wholly owned subsidiary Addex Therapeutics Ltd.6d agoNeurosterix announced plans to advance NTX-253 into Phase 2 clinical development.28d agoNeurosterix completed Phase 1 clinical studies evaluating NTX-253.28d ago